These three included TP53:ATRX in TCGA’s LGG cohort, TP53:KRAS in ICGC’s PAAD cohort, and KMT2D:BCL2 in ICGC’s German malignant lymphoma cohort (MALY-DE). This evidence concerns the gene KRAS and lymphoma.